Nuveen
BEAM icon

Nuveen’s Beam Therapeutics BEAM Stock Holding History

Nuveen’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.42M Buy
245,283
+12,687
+5% +$383K ﹤0.01% 1804
2026
Q1 		$5.54M Sell
232,596
-469
-0.2% -$13K ﹤0.01% 1835
2025
Q4 		$6.46M Sell
233,065
-4,275
-2% -$109K ﹤0.01% 1793
2025
Q3 		$5.76M Buy
237,340
+5,440
+2% +$108K ﹤0.01% 1839
2025
Q2 		$3.94M Buy
231,900
+32,020
+16% +$558K ﹤0.01% 1994
2025
Q1 		$3.9M Buy
199,880
+18,244
+10% +$478K ﹤0.01% 2042
2024
Q4 		$4.5M Sell
181,636
-2,960
-2% -$75.5K ﹤0.01% 2029
2024
Q3 		$4.52M Hold
184,596
– – ﹤0.01% 2036
2024
Q2 		$4.33M Buy
184,596
+10,405
+6% +$256K ﹤0.01% 2027
2024
Q1 		$5.76M Sell
174,191
-3,444
-2% -$107K ﹤0.01% 1913
2023
Q4 		$4.84M Sell
177,635
-3,055
-2% -$75.9K ﹤0.01% 1998
2023
Q3 		$4.35M Buy
180,690
+9,606
+6% +$258K ﹤0.01% 1936
2023
Q2 		$5.46M Sell
171,084
-30,057
-15% -$975K ﹤0.01% 1869
2023
Q1 		$6.16M Sell
201,141
-29,167
-13% -$1.15M ﹤0.01% 1772
2022
Q4 		$9.01M Sell
230,308
-12,649
-5% -$567K ﹤0.01% 1561
2022
Q3 		$11.6M Buy
242,957
+13,491
+6% +$770K ﹤0.01% 1392
2022
Q2 		$8.88M Buy
229,466
+17,413
+8% +$692K ﹤0.01% 1582
2022
Q1 		$12.5M Buy
212,053
+8,937
+4% +$586K ﹤0.01% 1500
2021
Q4 		$16.2M Buy
203,116
+7,619
+4% +$652K ﹤0.01% 1362
2021
Q3 		$20.1M Buy
195,497
+9,938
+5% +$998K 0.01% 1269
2021
Q2 		$23.9M Buy
185,559
+16,429
+10% +$1.31M 0.01% 1224
2021
Q1 		$13.5M Sell
169,130
-33,166
-16% -$3.16M ﹤0.01% 1607
2020
Q4 		$16.5M Buy
202,296
+71,925
+55% +$3.54M 0.01% 1372
2020
Q3 		$3.21M Buy
130,371
+68,697
+111% +$1.7M ﹤0.01% 2140
2020
Q2 		$1.73M Buy
61,674
+15,581
+34% +$336K ﹤0.01% 2404
2020
Q1 		$830K Buy
+46,093
New +$1M ﹤0.01% 2593

Other funds holding BEAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Nuveen's BEAM Position: Q2 2026 in Review

Nuveen increased its Beam Therapeutics (BEAM) stake by 5.5% in Q2 2026, buying an estimated $383K and bringing the position to 245,283 shares worth $8.42M. The position accounts for ﹤0.01% of the portfolio, ranked #1804.

Nuveen first reported a position in BEAM in Q1 2020 and has held it in 26 quarters since. The position peaked at $23.9M in Q2 2021. 277 funds tracked by Wall St. Rank hold BEAM as of Q2 2026.

  • Nuveen held 245,283 shares of Beam Therapeutics worth $8.42M as of Q2 2026.
  • Nuveen bought 12,687 Beam Therapeutics shares in Q2 2026, an estimated $383K.
  • Beam Therapeutics made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #1804 holding.
  • Nuveen first reported a position in Beam Therapeutics in Q1 2020 and has held it in 26 quarters since.
  • Nuveen's Beam Therapeutics position peaked at $23.9M in Q2 2021.
  • 277 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.